![]() |
JOURNAL TOOLS |
Publishing options |
eTOC |
To subscribe |
Submit an article |
Recommend to your librarian |
ARTICLE TOOLS |
Reprints |
Permissions |
Share |


YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
YOUR EBOOKS
COUPON
ACCESSIBILITY
CLINICAL CASES
Giornale Italiano di Dermatologia e Venereologia 2003 June;138(3):247-50
Copyright © 2003 EDIZIONI MINERVA MEDICA
language: Italian
Imiquimod: a role as a topical therapy for epidermo-dysplasia verruciformis?
Gisondi P. 1, Giordano G. 2, Bignardi L. 3, Gasperini M. 1, Zendri E. 1, Bassissi P. 1, De Panfilis G. 1
1 Sezione di Dermatologia Dipartimento di Scienze Chirurgiche Università degli Studi di Parma, Parma 2 Sezione di Anatomia e Istologia Patologica Dipartimento di Medicina di Laboratorio Università degli Studi di Parma, Parma 3 Sezione di Nefrologia e Scienze della Prevenzione Dipartimento di Clinica Medica Università degli Studi di Parma, Parma
The aim of this study is the evaluation of efficacy of imiquimod, an immmune response modifier that enhances the cell-mediated cytolytic antiviral activity, for the topical therapy of epidermodysplasia verruciformis (EV), a HPV-related disorder. The drug had never been used before for the therapy of EV. A 52-year-old woman, affected by EV-like syndrome associated with renal transplantation, has been treated by imiquimod, on occlusive dressing, 3 times a week, for 3 months. At the end of treatment a discrete improvement of the lesions was observed. The conclusion is drawn that imiquimod, topically applied, induces a partial improvement of the lesions due to EV, even if its use has been officially recognized only for the treatment of anogenital condylomata.